Testing New Formats for the Presentation of Research Evidence to Health Care Managers and Policy Makers
A Randomized Trial to Compare the Effects of a Novel Versus Traditional Systematic Review Format on the Ability of Health Care Managers and Policy Makers to Understand and Apply Evidence
調査の概要
詳細な説明
Despite advances in the conduct and reporting of traditional systematic reviews, current evidence suggests that they are used infrequently by health care managers and policy makers in decision making. Managers and policy makers have suggested that concise presentation positively affects the use of systematic reviews. The purpose of this randomized controlled trial is to assess the impact of a traditional systematic review format compared with the innovative format on the ability of health care managers and policy makers to understand the evidence in the review and apply it to a relevant health care decision making scenario.
The two end-user groups have different formatting needs and we will therefore run 2 parallel studies, randomizing each group separately. Once participants have consented to participate, a computer generated randomization process will allocate them to one of 2 arms (1:1 ratio). Participants will either receive either a traditional format or a novel format. Unequal block randomization will be used and allocation will be concealed through central assignment. Outcomes assessors will be blinded and participants will be blinded to the citation of the review so that the traditional version will not be easily accessible in its original format from the relevant journal.
This study will be the first study to engage health care managers and policy makers in the testing of formats for presentation of research evidence relevant to their needs. The results of the project will help increase the uptake of systematic review results in health care management policy decision-making, ultimately leading to informed decision making and positively impacting the health of Canadians.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ、M5B 1W8
- St. Michael's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Health care managers from the Alberta SCNs, CAHO in Ontario, the RHAs and AQESSS in Quebec and RHAs from BC will be invited to participate.
- Policy makers/analysts from the Ontario, BC, Alberta and Quebec Ministries of Health
Exclusion Criteria:
- Health care managers or policy makers who are unwilling or unable to give informed consent.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Novel systematic review format
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
|
A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
|
|
介入なし:Traditional systematic review format
Control participants will be asked to read and answer questions using a traditional systematic review format.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format
時間枠:This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
The proportion of participants (health care managers or policy makers) who appropriately consider and apply the evidence from each systematic review format to the scenario as measured by agreement with an expert panel's recommendation.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of appropriate application of the evidence.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measure will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Comprehension of the review
時間枠:This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Comprehension of the review - defined as the proportion of participants (health care managers or policy makers) who accurately define the bottom line from the systematic review as defined by an expert panel.
A panel of 4 health care managers or policy makers from our research team and 2 content experts.
Their answers will provide the definition of the bottom line from the systematic review.
Two investigators who will be blind to allocation will independently determine if the participant's answer agrees with that from the expert panel.
Disagreements will be resolved by a third investigator, independently.
Agreement between investigators will be reported using the kappa statistic.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Intention to use evidence
時間枠:This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Intention to use evidence - collected through a 12-item likert scale survey.
The survey has good face validity amongst policy makers and managers.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Perceived tentativeness of research findings
時間枠:This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Perceived tentativeness of research findings - collected through a 6-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
|
Provisional opinion about the intervention
時間枠:This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
Provisional opinion about the intervention - collected through a 14-item likert scale survey.
This has been pre-tested to make sure that the items are intelligible to people and to achieve high levels of face validity and reliability.
The mean and SD of each item in the survey will be reported and we will provide a summary score of all items and convert it to a percentage.
|
This measures will be assessed at the particular time the intervention is administered (i.e., at the time the participant reads the systematic review format, an average of 2 hours).
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Sharon e Straus、Unity Health Toronto
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- SMH-312381
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。